Top

Published in:

Open Access 01-08-2014 | Review

Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs

Authors: Abhineet Uppal, Mark K. Ferguson, Mitchell C. Posner, Samuel Hellman, Nikolai N. Khodarev, Ralph R. Weichselbaum

Published in: Clinical & Experimental Metastasis | Issue 6/2014

Abstract

Oligometastasis is a cancer disease state characterized by a limited number of metastatic tumors involving single or few organs and with biological properties that make them potentially amenable to locoregional antitumor therapy. Current clinical data show that they are potentially curable with surgical resection or/and radiotherapy. Yet, mechanisms of progression from primary tumor to oligometastasis, rather than to polymetastases, is lacking in detail. In the current review we focus on the role of micro-RNAs in the regulation of metastases development and the role they may play in the differentiation of oligometastatic from polymetastatic progression. We also discuss the analyses of metastatic samples from oligo-and polymetastatic patients, which suggest that oligometastasis is a distinct biologic entity regulated in part by micro-RNAs. In addition, a review of the known functions of oligometastatic-specific micro-RNAs suggest that they regulate multiple steps in the metastatic cascade, including epithelial–mesenchymal transition, tumor invasion, intravasation, distant vascular extravasation and proliferation in a distant organ. Understanding the role of micro-RNAs and their target genes in oligometastatic disease may allow for the development of targeted therapies to effectively conrol the spread of metastases.

Damin DC (2014) Evolving treatment strategies for colo. World J Gastroenterol 20:877–887. doi:10.3748/wjg.v20.i4.877 PubMedCentralPubMed

Giordano SH (2003) Update on locally advanced breast cancer. Oncologist 8(6):521–530PubMed

Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10PubMed

Niibe Y, Chang JY, Onishi H, Salama J, Hiraki T, Yamashita H (2013) Oligometastases/oligo-recurrence of lung cancer. Pulm Med 438236–3. doi: 10.1155/2013/438236

Withers HR, Lee SP (2006) Modeling growth kinetics and statistical distribution of oligometastases. Semin Radiat Oncol 16:111–119. doi:10.1016/j.semradonc.2005.12.006 PubMed

Lussier YA, Khodarev NN, Regan K, Corbin K, Li H, Ganai S, Khan SA, Gnerlich J, Darga TE, Fan H, Karpenko O, Paty PB, Posner MC, Chmura SJ, Hellman S, Ferguson MK, Weichselbaum RR (2012) Oligo-and polymetastatic progression in lung metastasis(es) patients is associated with specific MicroRNAs. PLoS One 7:e50141. doi:10.1371/journal.pone.0050141 PubMedCentralPubMed

Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318PubMedCentralPubMed

Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier P, Rubbia-Brandt L, Sobrero A, Tabernero J, Teh C, Van Cutsem E, Jean-Nicolas Vauthey of the EGOSLIM (Expert Group on OncoSurgery management of LIver Metastases) group (2012) The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. In: Oncologist. pp 1225–1239

Salah S, Watanabe K, Park JS, Addasi A, Park JW, Zabaleta J, Ardissone F, Kim J, Riquet M, Nojiri K, Gisabella M, Kim SY, Tanaka K (2013) Repeated resection of colorectal cancer pulmonary oligometastases: pooled analysis and prognostic assessment. Ann Surg Oncol 20:1955–1961. doi:10.1245/s10434-012-2860-y PubMed

10.

Milano MT, Katz AW, Muhs AG, Philip A, Buchholz DJ, Schell MC, Okunieff P (2007) A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer Res 112:650–658

11.

Fumagalli I, Bibault J-E, Dewas S, Kramar A, Mirabel X, Prevost B, Lacornerie T, Jerraya H, Lartigau E (2012) A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases. Radiat Oncol (London, England) 7:164. doi: 10.1186/1748-717X-7-164

12.

Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, Hawkins MA, Huddart RA, Nutting CM, Ostler PJ, van As NJ (2013) Stereotactic body radiotherapy for oligometastases. Lancet Oncol 14:e28–e37. doi:10.1016/S1470-2045(12)70510-7 PubMed

13.

Weichselbaum RR, Hellman S (2011) Oligometastases revisited. Nat Rev Clin Oncol 8:378–382. doi:10.1038/nrclinonc.2011.44 PubMed

14.

Corbin KS, Hellman S, Weichselbaum RR (2013) Extracranial oligometastases: a subset of metas. J Clin Oncol 31:1384–1390. doi:10.1200/JCO.2012.45.9651 PubMed

15.

Ashworth A, Rodrigues G, Boldt G, Palma D (2013) Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer 82:197–203. doi:10.1016/j.lungcan.2013.07.026 PubMed

16.

Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin M-L, McBride DJ, Varela I, Nik-Zainal SA, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Griffin CA, Burton J, Swerdlow H, Quail MA, Stratton MR, Iacobuzio-Donahue C, Futreal PA (2010) The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467:1109–1113. doi:10.1038/nature09460 PubMedCentralPubMed

17.

Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467:1114–1117. doi:10.1038/nature09515 PubMedCentralPubMed

18.

Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, Cook K, Stepansky A, Levy D, Esposito D, Muthuswamy L, Krasnitz A, McCombie WR, Hicks J, Wigler M (2011) Tumour evolution inferred by single-cell sequencing. Nature 472:90–94. doi:10.1038/nature09807 PubMed

19.

Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883–892. doi:10.1056/NEJMoa1113205 PubMed

20.

Klein CA (2013) Selection and adaptation during metastatic cancer progression. Nature 501:365–372. doi:10.1038/nature12628 PubMed

21.

Cairns J (1975) Mutation selection and the natural history of cancer. Nature 255:197–200PubMed

22.

Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194:23–28PubMed

23.

Kim MY, Oskarsson T, Acharyya S, Nguyen DX (2009) Tumor self-seeding by circulating cancer cells. Cell 139(7):1315–1326PubMedCentralPubMed

24.

Bozic I, Antal T, Ohtsuki H, Carter H, Kim D, Chen S, Karchin R, Kinzler KW, Vogelstein B, Nowak MA (2010) Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci USA 107:18545–18550. doi:10.1073/pnas.1010978107 PubMedCentralPubMed

25.

Gupta GP, Massagué J (2006) Cancer metastasis: building a framework. Cell 127:679–695. doi:10.1016/j.cell.2006.11.001 PubMed

26.

Chiang AC, Massagué J (2008) Molecular basis of metastasis. N Engl J Med 359:2814–2823. doi:10.1056/NEJMra0805239 PubMed

27.

Valastyan S, Weinberg RA (2011) Tumor metastasis: molecular insights and evolving paradigms. Cell 147:275–292. doi:10.1016/j.cell.2011.09.024 PubMedCentralPubMed

28.

Reymond N, d’Água BB, Ridley AJ (2013) Crossing the endothelial barrier during metastasis. Nat Rev Cancer 13:858–870. doi:10.1038/nrc3628 PubMed

29.

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. doi:10.1016/j.cell.2011.02.013 PubMed

30.

Khodarev NN, Yu J, Labay E, Darga T, Brown CK, Mauceri HJ, Yassari R, Gupta N, Weichselbaum RR (2003) Tumour-endothelium interactions in co-culture: coordinated changes of gene expression profiles and phenotypic properties of endothelial cells. J Cell Sci 116:1013–1022PubMed

31.

Geng Y, Chandrasekaran S, Hsu J-W, Gidwani M, Hughes AD, King MR (2013) Phenotypic switch in blood: effects of pro-inflammatory cytokines on breast cancer cell aggregation and adhesion. PLoS One 8:e54959. doi:10.1371/journal.pone.0054959 PubMedCentralPubMed

32.

Rückert F, Grützmann R, Pilarsky C (2012) Feedback within the inter-cellular communication and tumorigenesis in carcinomas. PLoS One 7:e36719. doi:10.1371/journal.pone.0036719 PubMedCentralPubMed

33.

Khodarev NN, Roach P, Pitroda SP, Golden DW, Bhayani M, Shao MY, Darga TE, Beveridge MG, Sood RF, Sutton HG, Beckett MA, Mauceri HJ, Posner MC, Weichselbaum RR (2009) STAT1 pathway mediates amplification of metastatic potential and resistance to therapy. PLoS One 4:e5821. doi:10.1371/journal.pone.0005821 PubMedCentralPubMed

34.

Efimova EV, Liang H, Pitroda SP, Labay E, Darga TE, Levina V, Lokshin A, Roizman B, Weichselbaum RR, Khodarev NN (2009) Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling. Int J Radiat Biol 85:421–431. doi:10.1080/09553000902838566 PubMedCentralPubMed

35.

Pitroda SP, Zhou T, Sweis RF, Filippo M, Labay E, Beckett MA, Mauceri HJ, Liang H, Darga TE, Perakis S, Khan SA, Sutton HG, Zhang W, Khodarev NN, Garcia JGN, Weichselbaum RR (2012) Tumor endothelial inflammation predicts clinical outcome in diverse human cancers. PLoS One 7:e46104. doi:10.1371/journal.pone.0046104 PubMedCentralPubMed

36.

Khodarev NN, Roizman B, Weichselbaum RR (2012) Molecular pathways: interferon/stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth. Can. Res, Clin. doi:10.1158/1078-0432.CCR-11-3225

37.

Kim VN (2005) MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 6:376–385. doi:10.1038/nrm1644 PubMed

38.

Melo SA, Esteller M (2014) Disruption of microRNA nuclear transport in human cancer. Semin Cancer Biol. doi:10.1016/j.semcancer.2014.02.012 PubMed

39.

Chekulaeva M, Filipowicz W (2009) Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells. Curr Opin Cell Biol 21:452–460. doi:10.1016/j.ceb.2009.04.009 PubMed

40.

Shen J, Xia W, Khotskaya YB, Huo L, Nakanishi K, Lim S-O, Du Y, Wang Y, Chang W-C, Chen C-H, Hsu JL, Wu Y, Lam YC, James BP, Liu X, Liu C-G, Patel DJ, Hung M-C (2013) EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature 497:383–387. doi:10.1038/nature12080 PubMedCentralPubMed

41.

Yang J-S, Smibert P, Westholm JO, Jee D, Maurin T, Lai EC (2013) Intertwined pathways for Argonaute-mediated microRNA biogenesis in Drosophila. Nucleic Acids Res. doi:10.1093/nar/gkt1038

42.

Heravi-Moussavi A, Anglesio MS, Cheng S-WG, Senz J, Yang W, Prentice L, Fejes AP, Chow C, Tone A, Kalloger SE, Hamel N, Roth A, Ha G, Wan ANC, Maines-Bandiera S, Salamanca C, Pasini B, Clarke BA, Lee AF, Lee C-H, Zhao C, Young RH, Aparicio SA, Sorensen PHB, Woo MMM, Boyd N, Jones SJM, Hirst M, Marra MA, Gilks B, Shah SP, Foulkes WD, Morin GB, Huntsman DG (2012) Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med 366:234–242. doi:10.1056/NEJMoa1102903 PubMed

43.

Witkos TM, Koscianska E, Krzyzosiak WJ (2011) Practical aspects of microRNA target prediction. Curr Mol Med 11:93–109PubMedCentralPubMed

44.

Lujambio A, Lowe SW (2012) The microcosmos of cancer. Nature 482:347–355. doi:10.1038/nature10888 PubMedCentralPubMed

45.

Lovat F, Valeri N, Croce CM (2011) MicroRNAs in the pathogenesis of cancer. Semin Oncol 38:724–733. doi:10.1053/j.seminoncol.2011.08.006 PubMed

46.

Bendoraite A, Knouf EC, Garg KS, Parkin RK, Kroh EM, O’Briant KC, Ventura AP, Godwin AK, Karlan BY, Drescher CW, Urban N, Knudsen BS, Tewari M (2010) Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol 116:117–125. doi:10.1016/j.ygyno.2009.08.009 PubMedCentralPubMed

47.

Korpal M, Lee ES, Hu G, Kang Y (2008) The miR-200 family inhibits epithelial–mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 283:14910–14914. doi:10.1074/jbc.C800074200 PubMedCentralPubMed

48.

D’Amato NC, Howe EN, Richer JK (2013) MicroRNA regulation of epithelial plasticity in cancer. Cancer Lett 341:46–55. doi:10.1016/j.canlet.2012.11.054 PubMed

49.

Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10:593–601. doi:10.1038/ncb1722 PubMed

50.

Ding X, Park SI, McCauley LK, Wang C-Y (2013) Signaling between transforming growth factor β (TGF-β) and transcription factor SNAI2 represses expression of microRNA miR-203 to promote epithelial–mesenchymal transition and tumor metastasis. J Biol Chem 288:10241–10253. doi:10.1074/jbc.M112.443655 PubMedCentralPubMed

51.

Valastyan S, Weinberg RA (2011) Roles for microRNAs in the regulation of cell adhesion molecules. J Cell Sci 124:999–1006. doi:10.1242/jcs.081513 PubMedCentralPubMed

52.

Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szász AM, Wang ZC, Brock JE, Richardson AL, Weinberg RA (2009) A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137:1032–1046. doi:10.1016/j.cell.2009.03.047 PubMedCentralPubMed

53.

Penna E, Orso F, Cimino D, Tenaglia E, Lembo A, Quaglino E, Poliseno L, Haimovic A, Osella-Abate S, De Pittà C, Pinatel E, Stadler MB, Provero P, Bernengo MG, Osman I, Taverna D (2011) microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J 30:1990–2007. doi:10.1038/emboj.2011.102 PubMedCentralPubMed

54.

Zhang Y-F, Zhang A-R, Zhang B-C, Rao Z-G, Gao J-F, Lv M-H, Wu Y-Y, Wang S-M, Wang R-Q, Fang D-C (2013) MiR-26a regulates cell cycle and anoikis of human esophageal adenocarcinoma cells through Rb1-E2F1 signaling pathway. Mol Biol Rep 40:1711–1720. doi:10.1007/s11033-012-2222-7 PubMed

55.

Aguda BD, Kim Y, Piper-Hunter MG, Friedman A, Marsh CB (2008) MicroRNA regulation of a cancer network: consequences of the feedback loops involving miR-17-92, E2F, and Myc. Proc Natl Acad Sci USA 105:19678–19683. doi:10.1073/pnas.0811166106 PubMedCentralPubMed

56.

Northcott PA, Fernandez-L A, Hagan JP, Ellison DW, Grajkowska W, Gillespie Y, Grundy R, Van Meter T, Rutka JT, Croce CM, Kenney AM, Taylor MD (2009) The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res 69:3249–3255. doi:10.1158/0008-5472.CAN-08-4710 PubMedCentralPubMed

57.

Fish JE, Srivastava D (2009) MicroRNAs: opening a new vein in angiogenesis research. Sci Signal 2:pe1–pe1. doi: 10.1126/scisignal.252pe1

58.

Guo C, Sah JF, Beard L, Willson JKV, Markowitz SD, Guda K (2008) The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosom Cancer 47:939–946. doi:10.1002/gcc.20596 PubMedCentralPubMed

59.

Liu Q, Lv G-D, Qin X, Gen Y-H, Zheng S-T, Liu T, Lu X-M (2012) Role of microRNA let-7 and effect to HMGA2 in esophageal squamous cell carcinoma. Mol Biol Rep 39:1239–1246. doi:10.1007/s11033-011-0854-7 PubMed

60.

Chan SY, Loscalzo J (2010) MicroRNA-210: a unique and pleiotropic hypoxamir. Cell Cycle 9:1072–1083PubMedCentralPubMed

61.

Pencheva N, Tavazoie SF (2013) Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol 15:546–554. doi:10.1038/ncb2769 PubMed

62.

Lussier YA, Xing HR, Salama JK, Khodarev NN, Huang Y, Zhang Q, Khan SA, Yang X, Hasselle MD, Darga TE, Malik R, Fan H, Perakis S, Filippo M, Corbin K, Lee Y, Posner MC, Chmura SJ, Hellman S, Weichselbaum RR (2011) MicroRNA expression characterizes oligometastasis(es). PLoS One 6:e28650. doi:10.1371/journal.pone.0028650 PubMedCentralPubMed

63.

Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen EEW, Connell PP, Haraf DJ, Vokes EE, Hellman S, Weichselbaum RR (2011) Stereotactic body radiotherapy for multisite extracranial oligometastases. Cancer Res 118:2962–2970. doi:10.1002/cncr.26611

64.

Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, Petrocca F, Martinvalet D, Song E, Lim B, Lieberman J (2009) miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One 4:e7181. doi:10.1371/journal.pone.0007181 PubMedCentralPubMed

65.

Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celià-Terrassa T, Mercatali L, Khan Z, Goodarzi H, Hua Y, Wei Y, Hu G, Garcia BA, Ragoussis J, Amadori D, Harris AL, Kang Y (2011) Direct targeting of Sec23a by miR-200 s influences cancer cell secretome and promotes metastatic colonization. Nat Med 17:1101–1108. doi:10.1038/nm.2401 PubMedCentralPubMed

66.

Yoshino H, Enokida H, Itesako T, Tatarano S, Kinoshita T, Fuse M, Kojima S, Nakagawa M, Seki N (2013) Epithelial–mesenchymal transition-related microRNA-200s regulate molecular targets and pathways in renal cell carcinoma. J Hum Genet 58:508–516. doi:10.1038/jhg.2013.31 PubMed

67.

Wang X, Chen X, Wang R, Xiao P, Xu Z, Chen L, Hang W, Ruan A, Yang H, Zhang X (2013) microRNA-200c modulates the epithelial-to-mesenchymal transition in human renal cell carcinoma metastasis. Oncol Rep 30:643–650. doi:10.3892/or.2013.2530

68.

Kurashige J, Kamohara H, Watanabe M, Hiyoshi Y, Iwatsuki M, Tanaka Y, Kinoshita K, Saito S, Baba Y, Baba H (2012) MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma. Ann Surg Oncol 19(Suppl 3):S656–S664. doi:10.1245/s10434-012-2217-6 PubMed

69.

Schliekelman MJ, Gibbons DL, Faca VM, Creighton CJ, Rizvi ZH, Zhang Q, Wong C-H, Wang H, Ungewiss C, Ahn Y-H, Shin D-H, Kurie JM, Hanash SM (2011) Targets of the tumor suppressor miR-200 in regulation of the epithelial–mesenchymal transition in cancer. Cancer Res 71:7670–7682. doi:10.1158/0008-5472.CAN-11-0964 PubMedCentralPubMed

70.

Teng Y, Mei Y, Hawthorn L, Cowell JK (2014) WASF3 regulates miR-200 inactivation by ZEB1 through suppression of KISS1 leading to increased invasiveness in breast cancer cells. Oncogene 33:203–211. doi:10.1038/onc.2012.565 PubMedCentralPubMed

71.

Guo L, Chen C, Shi M, Wang F, Chen X, Diao D, Hu M, Yu M, Qian L, Guo N (2013) Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial–mesenchymal transition. Oncogene 32:5272–5282. doi:10.1038/onc.2012.573 PubMed

72.

Castilla MÁ, Moreno-Bueno G, Romero-Pérez L, De Vijver KV, Biscuola M, López-García MÁ, Prat J, Matías-Guiu X, Cano A, Oliva E, Palacios J (2010) Micro-RNA signature of the epithelial–mesenchymal transition in endometrial carcinosarcoma. J Pathol 223:72–80. doi:10.1002/path.2802 PubMed

73.

Harazono Y, Muramatsu T, Endo H, Uzawa N, Kawano T, Harada K, Inazawa J, Kozaki K-I (2013) miR-655 Is an EMT-suppressive MicroRNA targeting ZEB1 and TGFBR2. PLoS One 8:e62757. doi:10.1371/journal.pone.0062757.s012 PubMedCentralPubMed

74.

Qiu X (2013) MiRNA-125a-3p is a negative regulator of the RhoA-actomyosin pathway in A549 cells. Int J Oncol 42:1734–1742. doi:10.3892/ijo.2013.1861 PubMed

75.

Qiao J, Lee S, Paul P, Theiss L, Tiao J, Qiao L, Kong A, Chung DH (2013) miR-335 and miR-363 regulation of neuroblastoma tumorigenesis and metastasis. Surgery 154:226–233. doi:10.1016/j.surg.2013.04.005 PubMed

76.

Anaya-Ruiz M, Bandala C, Perez-Santos JLM (2013) miR-485 acts as a tumor suppressor by inhibiting cell growth and migration in breast carcinoma T47D cells. Asian Pac J Cancer Prev 14:3757–3760PubMed

77.

Vaira V, Faversani A, Dohi T, Montorsi M, Augello C, Gatti S, Coggi G, Altieri DC, Bosari S (2012) miR-296 regulation of a cell polarity-cell plasticity module controls tumor progression. Oncogene 31:27–38. doi:10.1038/onc.2011.209 PubMedCentralPubMed

78.

Wu Z, Sun L, Wang H, Yao J, Jiang C, Xu W, Yang Z (2012) MiR-328 expression is decreased in high-grade gliomas and is associated with worse survival in primary glioblastoma. PLoS One 7:e47270. doi:10.1371/journal.pone.0047270.t003 PubMedCentralPubMed

79.

Kim JK, Noh JH, Jung KH, Eun JW, Bae HJ, Kim MG, Chang YG, Shen Q, Park WS, Lee JY, Borlak J, Nam SW (2013) Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology 57:1055–1067. doi:10.1002/hep.26101 PubMed

80.

Ding DP, Chen ZL, Zhao XH, Wang JW, Sun J, Wang Z, Tan FW, Tan XG, Li BZ, Zhou F, Shao K, Li N, Qiu B, He J (2011) miR-29c induces cell cycle arrest in esophageal squamous cell carcinoma by modulating cyclin E expression. Carcinogenesis 32:1025–1032. doi:10.1093/carcin/bgr078 PubMed

81.

Qiu T, Zhou X, Wang J, Du Y, Xu J, Huang Z, Zhu W, Shu Y, Liu P (2014) MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer. FEBS Lett 588:1168–1177. doi:10.1016/j.febslet.2014.02.054 PubMed

82.

Nakano H, Yamada Y, Miyazawa T, Yoshida T (2013) Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells. Int J Oncol 42:1875–1882. doi:10.3892/ijo.2013.1896 PubMedCentralPubMed

83.

Guo X, Guo L, Ji J, Zhang J, Zhang J, Chen X, Cai Q, Li J, Gu Q, Liu B, Zhu Z, Yu Y (2010) miRNA-331-3p directly targets E2F1 and induces growth arrest in human gastric cancer. Biochem Biophys Res Commun 398:1–6. doi:10.1016/j.bbrc.2010.05.082 PubMed

84.

Xiao B, Tan L, He B, Liu Z, Xu R (2013) MiRNA-329 targeting E2F1 inhibits cell proliferation in glioma cells. J Transl Med 11:172. doi:10.1186/1479-5876-11-172 PubMedCentralPubMed

85.

Zhai H, Song B, Xu X, Zhu W, Ju J (2012) Inhibition of autophagy and tumor growth in colon cancer by miR-502. Oncogene 32:1570–1579. doi:10.1038/onc.2012.167 PubMedCentralPubMed

86.

Kim Y-K, Yu J, Han TS, Park S-Y, Namkoong B, Kim DH, Hur K, Yoo M-W, Lee H-J, Yang H-K, Kim VN (2009) Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res 37:1672–1681. doi:10.1093/nar/gkp002 PubMedCentralPubMed

87.

Pickering MT, Stadler BM, Kowalik TF (2009) miR-17 and miR-20a temper an E2F1-induced G1 checkpoint to regulate cell cycle progression. Oncogene 28:140–145. doi:10.1038/onc.2008.372 PubMedCentralPubMed

88.

Harazono Y, Muramatsu T, Endo H, Uzawa N, Kawano T, Harada K, Inazawa J, Kozaki K-I (2013) miR-655 Is an EMT-suppressive microRNA targeting ZEB1 and TGFBR2. PLoS One 8:e62757. doi:10.1371/journal.pone.0062757 PubMedCentralPubMed

89.

Xin C, Zhang H, Liu Z (2014) miR-154 suppresses colorectal cancer cell growth and motility by targeting TLR2. Mol Cell Biochem 387:271–277. doi:10.1007/s11010-013-1892-3 PubMed

90.

Zhu C, Li J, Cheng G, Zhou H, Tao L, Cai H, Li P, Cao Q, Ju X, Meng X, Wang M, Zhang Z, Qin C, Hua L, Yin C, Shao P (2013) miR-154 inhibits EMT by targeting HMGA2 in prostate cancer cells. Mol Cell Biochem 379:69–75. doi:10.1007/s11010-013-1628-4 PubMed

91.

Zhu C, Shao P, Bao M, Li P, Zhou H, Cai H, Cao Q, Tao L, Meng X, Ju X, Qin C, Li J, Yin C (2014) miR-154 inhibits prostate cancer cell proliferation by targeting CCND2. Urol Oncol 32(31):e9–e16. doi:10.1016/j.urolonc.2012.11.013 PubMed

92.

Qu S, Yao Y, Shang C, Xue Y, Ma J, Li Z, Liu Y (2012) MicroRNA-330 is an oncogenic factor in glioblastoma cells by regulating SH3GL2 gene. PLoS One 7:e46010. doi:10.1371/journal.pone.0046010 PubMedCentralPubMed

93.

Jeyapalan Z, Deng Z, Shatseva T, Fang L, He C, Yang BB (2011) Expression of CD44 3’-untranslated region regulates endogenous microRNA functions in tumorigenesis and angiogenesis. Nucleic Acids Res 39:3026–3041. doi:10.1093/nar/gkq1003 PubMedCentralPubMed

94.

Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, Nguyen A, Chanthery Y, Lim L, Ashton LJ, Judson RL, Huskey N, Blelloch R, Haber M, Norris MD, Lengyel P, Hackett CS, Preiss T, Chetcuti A, Sullivan CS, Marcusson EG, Weiss W, L’Etoile N, Goga A (2010) miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat Med 16:1134–1140. doi:10.1038/nm.2227 PubMedCentralPubMed

95.

Bao L, Hazari S, Mehra S, Kaushal D, Moroz K, Dash S (2012) Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol 180:2490–2503. doi:10.1016/j.ajpath.2012.02.024 PubMedCentralPubMed

96.

Anaya-Ruiz M, Cebada J, Delgado-López G, Sánchez-Vázquez ML, Perez-Santos JLM (2013) miR-153 silencing induces apoptosis in the MDA-MB-231 breast cancer cell line. Asian Pac J Cancer Prev 14:2983–2986PubMed

97.

Myatt SS, Wang J, Monteiro LJ, Christian M, Ho K-K, Fusi L, Dina RE, Brosens JJ, Ghaem-Maghami S, Lam EW-F (2010) Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res 70:367–377. doi:10.1158/0008-5472.CAN-09-1891 PubMedCentralPubMed

98.

Zhao S, Deng Y, Liu Y, Chen X, Yang G, Mu Y, Zhang D, Kang J, Wu Z (2013) MicroRNA-153 is tumor suppressive in glioblastoma stem cells. Mol Biol Rep 40:2789–2798. doi:10.1007/s11033-012-2278-4 PubMed

99.

Yoon A-R, Gao R, Kaul Z, Choi I-K, Ryu J, Noble JR, Kato Y, Saito S, Hirano T, Ishii T, Reddel RR, Yun C-O, Kaul SC, Wadhwa R (2011) MicroRNA-296 is enriched in cancer cells and downregulates p21WAF1 mRNA expression via interaction with its 3’ untranslated region. Nucleic Acids Res 39:8078–8091. doi:10.1093/nar/gkr492 PubMedCentralPubMed

100.

Savi F, Forno I, Faversani A, Luciani A, Caldiera S, Gatti S, Foa P, Ricca D, Bulfamante G, Vaira V, Bosari S (2014) MiR-296/Scribble axe is deregulated in human breast cancer and miR-296 restoration reduces tumor growth in vivo. Clin Sci 127:233–242. doi:10.1042/CS20130580 PubMed

101.

Bai Y, Liao H, Liu T, Zeng X, Xiao F, Luo L, Guo H, Guo L (2013) MiR-296-3p regulates cell growth and multi-drug resistance of human glioblastoma by targeting ether-à-go-go (EAG1). Eur J Cancer 49:710–724. doi:10.1016/j.ejca.2012.08.020 PubMed

102.

Wei JJ, Wu X, Peng Y, Shi G, Olca B, Yang X, Daniels G, Osman I, Ouyang J, Hernando E, Pellicer A, Rhim JS, Melamed J, Lee P (2011) Regulation of HMGA1 expression by MicroRNA-296 affects prostate cancer growth and invasion. Clin Cancer Res 17:1297–1305. doi:10.1158/1078-0432.CCR-10-0993 PubMedCentralPubMed

103.

Li Q-Q, Chen Z-Q, Cao X-X, Xu J-D, Xu J-W, Chen Y-Y, Wang W-J, Chen Q, Tang F, Liu X-P, Xu Z-D (2011) Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial–mesenchymal transition of breast cancer cells. Cell Death Differ 18:16–25. doi:10.1038/cdd.2010.103 PubMedCentralPubMed

104.

Wu Z-S, Wang C-Q, Xiang R, Liu X, Ye S, Yang X-Q, Zhang G-H, Xu X-C, Zhu T, Wu Q (2012) Loss of miR-133a expression associated with poor survival of breast cancer and restoration of miR-133a expression inhibited breast cancer cell growth and invasion. BMC Cancer 12:51. doi:10.1186/1471-2407-12-51 PubMedCentralPubMed

105.

Kojima S, Chiyomaru T, Kawakami K, Yoshino H, Enokida H, Nohata N, Fuse M, Ichikawa T, Naya Y, Nakagawa M, Seki N (2012) Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J Cancer 106:405–413. doi:10.1038/bjc.2011.462 PubMedCentralPubMed

106.

Yoshino H, Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Nishiyama K, Nohata N, Seki N, Nakagawa M (2011) The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer 104:808–818. doi:10.1038/bjc.2011.23 PubMedCentralPubMed

107.

Pan Y-Z, Morris ME, Yu A-M (2009) MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol 75:1374–1379. doi:10.1124/mol.108.054163 PubMedCentralPubMed

108.

Xu XT, Xu Q, Tong JL, Zhu MM, Nie F, Chen X, Xiao SD, Ran ZH (2012) MicroRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer. Br J Cancer 106:1320–1330. doi:10.1038/bjc.2012.88 PubMedCentralPubMed

109.

Paduano F, Dattilo V, Narciso D, Bilotta A, Gaudio E, Menniti M, Agosti V, Palmieri C, Perrotti N, Fusco A, Trapasso F, Iuliano R (2013) Protein tyrosine phosphatase PTPRJ is negatively regulated by microRNA-328. FEBS J 280:401–412. doi:10.1111/j.1742-4658.2012.08624.x PubMed

110.

Li W-Q, Li Y-M, Tao B-B, Lu Y-C, Hu G-H, Liu H-M, He J, Xu Y, Yu H-Y (2010) Downregulation of ABCG2 expression in glioblastoma cancer stem cells with miRNA-328 may decrease their chemoresistance. Med Sci Monit 16:HY27–HY30PubMed

111.

Fang C, Zhao Y, Guo B (2013) MiR-199b-5p targets HER2 in breast cancer cells. J Cell Biochem 114:1457–1463. doi:10.1002/jcb.24487 PubMed

112.

Garzia L, Andolfo I, Cusanelli E, Marino N, Petrosino G, De Martino D, Esposito V, Galeone A, Navas L, Esposito S, Gargiulo S, Fattet S, Donofrio V, Cinalli G, Brunetti A, Vecchio LD, Northcott PA, Delattre O, Taylor MD, Iolascon A, Zollo M (2009) MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One 4:e4998. doi:10.1371/journal.pone.0004998 PubMedCentralPubMed

113.

Andolfo I, Liguori L, De Antonellis P, Cusanelli E, Marinaro F, Pistollato F, Garzia L, De Vita G, Petrosino G, Accordi B, Migliorati R, Basso G, Iolascon A, Cinalli G, Zollo M (2012) The micro-RNA 199b-5p regulatory circuit involves Hes1, CD15, and epigenetic modifications in medulloblastoma. Neuro-oncology 14:596–612. doi:10.1093/neuonc/nos002 PubMedCentralPubMed

114.

Ninio-Many L, Grossman H, Shomron N, Chuderland D, Shalgi R (2013) microRNA-125a-3p reduces cell proliferation and migration by targeting Fyn. J Cell Sci 126:2867–2876. doi:10.1242/jcs.123414 PubMed

115.

Chen J, Chen Y, Chen Z (2013) MiR-125a/b regulates the activation of cancer stem cells in paclitaxel-resistant colon cancer. Cancer Invest 31:17–23. doi:10.3109/07357907.2012.743557 PubMed

116.

Sun Y-M, Lin K-Y, Chen Y-Q (2013) Diverse functions of miR-125 family in different cell contexts. J Hematol Oncol 6:6. doi:10.1186/1756-8722-6-6 PubMedCentralPubMed

117.

Bi Q, Tang S, Xia L, Du R, Fan R, Gao L, Jin J, Liang S, Chen Z, Xu G, Nie Y, Wu K, Liu J, Shi Y, Ding J, Fan D (2012) Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PLoS One 7:e40169. doi:10.1371/journal.pone.0040169 PubMedCentralPubMed

118.

Kim S-W, Ramasamy K, Bouamar H, Lin A-P, Jiang D, Aguiar RCT (2012) MicroRNAs miR-125a and miR-125b constitutively activate the NF-κB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci USA 109:7865–7870. doi:10.1073/pnas.1200081109 PubMedCentralPubMed

119.

Yang H, Fang F, Chang R, Yang L (2013) MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor β receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. Hepatology 58:205–217. doi:10.1002/hep.26315 PubMed

120.

Fan Y-C, Mei P-J, Chen C, Miao F-A, Zhang H, Li Z-L (2013) MiR-29c inhibits glioma cell proliferation, migration, invasion and angiogenesis. J Neurooncol 115:179–188. doi:10.1007/s11060-013-1223-2 PubMed

121.

Wang H, Zhu Y, Zhao M, Wu C, Zhang P, Tang L, Zhang H, Chen X, Yang Y, Liu G (2013) miRNA-29c suppresses lung cancer cell adhesion to extracellular matrix and metastasis by targeting integrin β1 and matrix metalloproteinase2 (MMP2). PLoS One 8:e70192. doi:10.1371/journal.pone.0070192 PubMedCentralPubMed

122.

Bae HJ, Noh JH, Kim JK, Eun JW, Jung KH, Kim MG, Chang YG, Shen Q, Kim S-J, Park WS, Lee JY, Nam SW (2013) MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma. Oncogene. doi: 10.1038/onc.2013.216

123.

Wang C-M, Wang Y, Fan C-G, Xu F-F, Sun W-S, Liu Y-G, Jia J-H (2011) miR-29c targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. Biochem Biophys Res Commun 411:586–592. doi:10.1016/j.bbrc.2011.06.191 PubMed

124.

Liu N, Tang L-L, Sun Y, Cui R-X, Wang H-Y, Huang B-J, He Q-M, Jiang W, Ma J (2013) MiR-29c suppresses invasion and metastasis by targeting TIAM1 in nasopharyngeal carcinoma. Cancer Lett 329:181–188. doi:10.1016/j.canlet.2012.10.032 PubMed

125.

Kikkawa N, Hanazawa T, Fujimura L, Nohata N, Suzuki H, Chazono H, Sakurai D, Horiguchi S, Okamoto Y, Seki N (2010) miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC). Br J Cancer 103:877–884. doi:10.1038/sj.bjc.6605811 PubMedCentralPubMed

126.

Uhlmann S, Mannsperger H, Zhang JD, Horvat E-Á, Schmidt C, Küblbeck M, Henjes F, Ward A, Tschulena U, Zweig K, Korf U, Wiemann S, Sahin O (2012) Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer. Mol Syst Biol 8:570. doi:10.1038/msb.2011.100 PubMedCentralPubMed

127.

Iliopoulos D, Rotem A, Struhl K (2011) Inhibition of miR-193a expression by Max and RXRα activates K-Ras and PLAU to mediate distinct aspects of cellular transformation. Cancer Res 71:5144–5153. doi:10.1158/0008-5472.CAN-11-0425 PubMedCentralPubMed

128.

Ory B, Ramsey MR, Wilson C, Vadysirisack DD, Forster N, Rocco JW, Rothenberg SM, Ellisen LW (2011) A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma. J Clin Invest 121:809–820. doi:10.1172/JCI43897 PubMedCentralPubMed

129.

Kozaki KI, Imoto I, Mogi S, Omura K, Inazawa J (2008) Exploration of tumor-suppressive MicroRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 68:2094–2105. doi:10.1158/0008-5472.CAN-07-5194 PubMed

130.

Hsu K-W, Wang A-M, Ping Y-H, Huang K-H, Huang T-T, Lee H-C, Lo S-S, Chi C-W, Yeh T-S (2014) Downregulation of tumor suppressor MBP-1 by microRNA-363 in gastric carcinogenesis. Carcinogenesis 35:208–217. doi:10.1093/carcin/bgt285 PubMed

131.

Sun Q, Zhang J, Cao W, Wang X, Xu Q, Yan M, Wu X, Chen W (2013) Dysregulated miR-363 affects head and neck cancer invasion and metastasis by targeting podoplanin. Int J Biochem Cell Biol 45:513–520. doi:10.1016/j.biocel.2012.12.004 PubMed

Title: Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs
Authors: Abhineet Uppal
Mark K. Ferguson
Mitchell C. Posner
Samuel Hellman
Nikolai N. Khodarev
Ralph R. Weichselbaum
Publication date: 01-08-2014
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 6/2014
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-014-9664-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2014

Living in shear: platelets protect cancer cells from shear induced damage

Ascites-induced shift along epithelial-mesenchymal spectrum in ovarian cancer cells: enhancement of their invasive behavior partly dependant on αv integrins

High expression of S100A4 and endoglin is associated with metastatic disease in head and neck squamous cell carcinoma

Diet modulation is an effective complementary agent in preventing and treating breast cancer lung metastasis

FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion

ADRM1 gene amplification is a candidate driver for metastatic gastric cancers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer